Expert Analysis

First-Line Therapy and Switch Strategies

Source: CCO Official Conference Coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

First-Line Therapy and Switch Strategies

Faculty:

David A. Cooper, MD, DSc
Joel E. Gallant, MD, MPH
Kathleen E. Squires, MD

CREDIT INFORMATION

Release Date: September 27, 2007

Expiration Date: September 26, 2008

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing contact hours

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent data on first-line antiretroviral therapy options
Describe the results of recent clinical studies concerning switch strategies
Describe findings concerning antiretroviral therapy initiation in treatment-naive populations

Topics covered include:

SMART Subgroup Analysis in Naive and Untreated Patients
Maraviroc vs Efavirenz in Treatment-Naive Patients
Raltegravir vs Efavirenz in Treatment-Naive Patients
Long-term Follow-up of Tenofovir-Based Regimens
Switching NRTIs to Tenofovir/Emtricitabine or Abacavir/Lamivudine
Boosted Saquinavir vs Boosted Lopinavir in Treatment-Naive Patients
Boosted Atazanavir vs Boosted Fosamprenavir in Treatment-Naive Patients
Boosted vs Unboosted Atazanavir in Treatment-Naive Patients
Lopinavir/Ritonavir Plus 1 or More NRTIs in Therapy-Naive Patients
Lopinavir/Ritonavir Monotherapy in Therapy-Naive Patients
Early vs Later Antiretroviral Initiation in HIV-Infected Infants
Conclusion

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.